$CLSD
Clearside Biomedical, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018020519 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $0.00 $130.0K
YoY Change -100.0% 2500.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.560M $2.290M
YoY Change 55.46% 136.08%
% of Gross Profit
Research & Development $17.34M $11.48M
YoY Change 51.1% 172.44%
% of Gross Profit
Depreciation & Amortization $40.00K $60.00K
YoY Change -33.33% 500.0%
% of Gross Profit
Operating Expenses $20.90M $13.77M
YoY Change 51.83% 165.64%
Operating Profit -$20.90M -$13.64M
YoY Change 53.28% 163.38%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $203.0K -$135.0K
YoY Change -250.37% -277.63%
Pretax Income -$20.70M -$13.77M
YoY Change 50.33% 170.0%
Income Tax
% Of Pretax Income
Net Earnings -$20.70M -$13.77M
YoY Change 50.3% 169.95%
Net Earnings / Revenue -10594.62%
Basic Earnings Per Share
Diluted Earnings Per Share -$647.3K -$544.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.40M $66.04M
YoY Change 27.81% 19.41%
Cash & Equivalents $35.19M $16.68M
Short-Term Investments $49.20M $49.36M
Other Short-Term Assets $2.400M $292.0K
YoY Change 721.92% 1617.65%
Inventory
Prepaid Expenses $675.0K
Receivables
Other Receivables
Total Short-Term Assets $86.80M $67.00M
YoY Change 29.55% 19.58%
LONG-TERM ASSETS
Property, Plant & Equipment $800.0K $963.0K
YoY Change -16.93% 676.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $90.00K
YoY Change 344.44% 1185.71%
Total Long-Term Assets $1.200M $1.413M
YoY Change -15.07% 978.63%
TOTAL ASSETS
Total Short-Term Assets $86.80M $67.00M
Total Long-Term Assets $1.200M $1.413M
Total Assets $88.00M $68.42M
YoY Change 28.63% 21.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.400M $3.732M
YoY Change 125.08% 57.73%
Accrued Expenses $2.400M $1.639M
YoY Change 46.43% -15.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $1.600M
YoY Change -100.0% -33.33%
Total Short-Term Liabilities $10.90M $7.136M
YoY Change 52.75% 5.99%
LONG-TERM LIABILITIES
Long-Term Debt $9.848M $6.196M
YoY Change 58.94% 87.76%
Other Long-Term Liabilities $600.0K $800.0K
YoY Change -25.0% 912.66%
Total Long-Term Liabilities $9.848M $6.196M
YoY Change 58.94% 7743.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.90M $7.136M
Total Long-Term Liabilities $9.848M $6.196M
Total Liabilities $21.30M $14.09M
YoY Change 51.18% 37.21%
SHAREHOLDERS EQUITY
Retained Earnings -$161.4M -$89.39M
YoY Change 80.52% 79.09%
Common Stock $32.00K $25.00K
YoY Change 28.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.66M $54.33M
YoY Change
Total Liabilities & Shareholders Equity $88.02M $68.42M
YoY Change 28.65% 21.81%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$20.70M -$13.77M
YoY Change 50.3% 169.95%
Depreciation, Depletion And Amortization $40.00K $60.00K
YoY Change -33.33% 500.0%
Cash From Operating Activities -$19.57M -$11.55M
YoY Change 69.44% 110.77%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$32.83M $5.090M
YoY Change -744.99%
Cash From Investing Activities -$32.83M $5.080M
YoY Change -746.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.740M 160.0K
YoY Change 1612.5% -99.64%
NET CHANGE
Cash From Operating Activities -19.57M -11.55M
Cash From Investing Activities -32.83M 5.080M
Cash From Financing Activities 2.740M 160.0K
Net Change In Cash -49.66M -6.310M
YoY Change 687.0% -116.02%
FREE CASH FLOW
Cash From Operating Activities -$19.57M -$11.55M
Capital Expenditures -$10.00K
Free Cash Flow -$11.54M
YoY Change 110.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
360000
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
32000
CY2018Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
550000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
610000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20000
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
228007000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13519000
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9848000
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
145618000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
clsd:LicenseAndCollaborationMember
CY2017Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
clsd:LicenseAndCollaborationMember
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
clsd:LicenseAndCollaborationMember
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24156000
clsd Accretion Of Final Payment Of Amount Borrowed
AccretionOfFinalPaymentOfAmountBorrowed
60000
clsd Accretion Of Final Payment Of Amount Borrowed
AccretionOfFinalPaymentOfAmountBorrowed
105000
CY2018Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2017Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
53000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
66672000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21415000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88016000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-161368000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124220000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40493000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32024223
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25354651
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32024223
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25354651
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
130000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
135000
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
clsd:LicenseAndCollaborationMember
us-gaap Depreciation
Depreciation
94000
us-gaap Depreciation
Depreciation
87000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
244000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
830000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
640000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-10000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
49000
clsd Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
70000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35222000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22529000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
52446000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
25603000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
31870000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
49245000
CY2018Q2 clsd Fair Value Assets Between Level1 Level2 And Level3 Transfers Amount
FairValueAssetsBetweenLevel1Level2AndLevel3TransfersAmount
0
us-gaap Share Based Compensation
ShareBasedCompensation
2337000
us-gaap Share Based Compensation
ShareBasedCompensation
1531000
us-gaap Paid In Kind Interest
PaidInKindInterest
60000
us-gaap Paid In Kind Interest
PaidInKindInterest
105000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37299000
us-gaap Deferred Finance Costs Own Share Lending Arrangement Issuance Costs Amortization Expense1
DeferredFinanceCostsOwnShareLendingArrangementIssuanceCostsAmortizationExpense1
79000
us-gaap Deferred Finance Costs Own Share Lending Arrangement Issuance Costs Amortization Expense1
DeferredFinanceCostsOwnShareLendingArrangementIssuanceCostsAmortizationExpense1
105000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-30000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
239000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
48000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
195000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
45000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
8300000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5292000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25961000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
25010000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
319000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20576000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-912000
clsd Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
79581000
clsd Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
5057000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
433000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
40000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
81759000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18149000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9584000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35184000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35545000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17035000
clsd Noncash Tenant Improvements Paid By Landlord
NoncashTenantImprovementsPaidByLandlord
637000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the accounting for useful lives to calculate depreciation and amortization, clinical trial estimates and related accrued liabilities, share-based compensation expense and income tax valuation allowance. Actual results could differ from these estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company maintains its cash in bank deposits that at times may exceed federally insured limits. The Company has not experienced any loss in such accounts. The Company believes it is not exposed to any significant risks with respect to its cash balances.</p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2011-05-26
CY2018Q1 clsd Stock Issued During Period Shares Follow On Offering
StockIssuedDuringPeriodSharesFollowOnOffering
6538462
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
13.00
CY2018Q1 clsd Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
79600000
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
84400000
clsd Short Term Investments Maturity Period Range Start
ShortTermInvestmentsMaturityPeriodRangeStart
P90D
clsd Short Term Investments Maturity Period Range End
ShortTermInvestmentsMaturityPeriodRangeEnd
P365D
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16675000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
360000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1123000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1132000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
332000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
247000
CY2018Q2 clsd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1208000
CY2017Q4 clsd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3360000
CY2018Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
554000
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
920000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
68000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
62000
CY2018Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
88000
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
113000
CY2018Q2 us-gaap Interest Payable Current
InterestPayableCurrent
71000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
58000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
379000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
203000
CY2018Q2 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
186000
CY2017Q2 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
162000
us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
346000
us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
317000
CY2018Q2 clsd Accretion Of Final Payment Of Amount Borrowed
AccretionOfFinalPaymentOfAmountBorrowed
11000
CY2017Q2 clsd Accretion Of Final Payment Of Amount Borrowed
AccretionOfFinalPaymentOfAmountBorrowed
53000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2451000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
23000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
105000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
217000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
444000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
458000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
472000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
860000
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
58000
CY2017Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
58000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
116000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
98000
CY2017Q4 clsd Fair Value Assets Between Level1 Level2 And Level3 Transfers Amount
FairValueAssetsBetweenLevel1Level2AndLevel3TransfersAmount
0
CY2018Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
84790000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
38000000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3250296

Files In Submission

Name View Source Status
0001564590-18-020519-index-headers.html Edgar Link pending
0001564590-18-020519-index.html Edgar Link pending
0001564590-18-020519.txt Edgar Link pending
0001564590-18-020519-xbrl.zip Edgar Link pending
clsd-10q_20180630.htm Edgar Link pending
clsd-20180630.xml Edgar Link completed
clsd-20180630.xsd Edgar Link pending
clsd-20180630_cal.xml Edgar Link unprocessable
clsd-20180630_def.xml Edgar Link unprocessable
clsd-20180630_lab.xml Edgar Link unprocessable
clsd-20180630_pre.xml Edgar Link unprocessable
clsd-ex101_147.htm Edgar Link pending
clsd-ex102_146.htm Edgar Link pending
clsd-ex311_7.htm Edgar Link pending
clsd-ex312_6.htm Edgar Link pending
clsd-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending